Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

20.05
-0.1600-0.79%
Pre-market: 20.900.8500+4.24%04:15 EDT
Volume:658.99K
Turnover:13.27M
Market Cap:1.46B
PE:-33.15
High:20.89
Open:20.10
Low:19.90
Close:20.21
Loading ...

Kiniksa : Has Exercised Its Right to Terminate Its Exclusive License Agreement for Mavrilimumab With Medimmune

THOMSON REUTERS
·
25 Feb

Kiniksa Pharmaceuticals International Plc: to Discontinue Abiprubart Development in SjÖGren's Disease

THOMSON REUTERS
·
25 Feb

Kiniksa Pharmaceuticals International Plc - Arcalyst 2025 Net Product Revenue Expected $560-$580 Million

THOMSON REUTERS
·
25 Feb

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

GlobeNewswire
·
25 Feb

Evercore ISI Reaffirms Their Buy Rating on Kiniksa Pharmaceuticals (KNSA)

TIPRANKS
·
04 Feb

Exploring High Growth Tech Stocks in the United States

Simply Wall St.
·
29 Jan

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?

Zacks
·
14 Jan

Kiniksa Pharmaceuticals Reports Preliminary Q4 And FY2024 Arcalyst Net Product Revenue Of $121.9M And $416.4M, Respectively

Benzinga
·
13 Jan

Kiniksa Pharmaceuticals International - Arcalyst 2025 Net Product Revenue Expected $560-$580 Million

THOMSON REUTERS
·
13 Jan

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

GlobeNewswire
·
13 Jan

Kiniksa Pharmaceuticals (KNSA) Gets a Buy from Jefferies

TIPRANKS
·
05 Jan

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.
·
20 Dec 2024

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

GlobeNewswire
·
27 Nov 2024

Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025?

Insider Monkey
·
13 Nov 2024

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

GlobeNewswire
·
13 Nov 2024

Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
06 Nov 2024

Kiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Simply Wall St.
·
01 Nov 2024

Kiniksa Pharmaceuticals Faces Financial Risks from Global Currency Fluctuations

TIPRANKS
·
31 Oct 2024

Kiniksa Pharmaceuticals International Third Quarter 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
30 Oct 2024

Analysts’ Top Healthcare Picks: BioMarin Pharmaceutical (BMRN), Kiniksa Pharmaceuticals (KNSA)

TIPRANKS
·
30 Oct 2024